Want to see PTHS full AI Analyst Report?
PTHS Stock Chart & Stats
$25.92
$1.67(6.44%)
At close: 4:00 PM EDT
$25.92
$1.67(6.44%)
Day’s Range― - ―
52-Week Range$16.50 - $37.50
Previous Close$27.59
Volume91.43K
Average Volume (3M)30.94K
Market Cap
$95.89M
Enterprise Value$38.22M
Total Cash (Recent Filing)$32.23M
Total Debt (Recent Filing)$52.93M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 24, 2026EPS Estimate
-2.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-40.69
Shares Outstanding3,475,645
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit2.93
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$61.20Price Target Upside136.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-10.35
Revenue Forecast (FY)$63.77M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginRecent scaling of revenue alongside a ~63% gross margin indicates attractive unit economics that can support operating leverage as commercialization matures. Durable margin strength helps profitability as SG&A growth moderates and subsequent product launches leverage fixed commercial costs over 2–6 months.
Commercial Launch TractionSustained quarter-over-quarter prescription and revenue growth demonstrates real market demand and effective sales execution. Strong prescriber expansion and repeated monthly/weekly gains signal durable adoption that underpins repeatable revenue streams and supports expansion of the dermatology franchise over the next several quarters.
Improved Liquidity / FinancingRecent debt facility draw and higher cash/working capital materially extend runway for ongoing launches and planned product rollouts. This financing flexibility reduces immediate dilution risk and gives management time to convert early commercial traction into stronger cash generation before next financing necessity.
Bears Say
Large Net Losses & Cash BurnSustained large net losses and negative operating cash flow mean the business remains reliant on external funding. Persistent cash burn erodes flexibility and could force dilutive financings or constrained investment if revenue growth or margins fail to accelerate sufficiently within the next several quarters.
High SG&A And Negative Adjusted EBITDAElevated commercial and administrative spending, coupled with negative adjusted EBITDA and rising interest costs, compresses near-term operating leverage. If sales productivity or per-unit economics stall, sustained high SG&A will prolong the path to profitability and increase financing needs over the medium term.
Rising Gross-to-Net And COGS TimingAn expected increase in gross-to-net deductions reduces realized revenue per unit and will pressure margins even if WAC stays constant. Coupled with inventory accounting timing from merger-related step-ups, COGS normalization may be volatile, hindering predictable cash conversion over the next 2–6 months.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $16.50 and its highest was $37.50 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $95.89M.
When is Pelthos Therapeutics’s upcoming earnings report date?
Pelthos Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 26 days.
How were Pelthos Therapeutics’s earnings last quarter?
Pelthos Therapeutics released its earnings results on May 14, 2026. The company reported -$3.09 earnings per share for the quarter, beating the consensus estimate of -$3.45 by $0.36.
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate is -2.82.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,475,645 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Pelthos Therapeutics reported an EPS of -$3.09 in its last earnings report, beating expectations of -$3.45. Following the earnings report the stock price went up 6.459%.
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.20 (136.11% Upside)
$61.20 (136.11% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 201.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $959.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
315.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
PTHS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive commercialization story: strong prescription growth (25% QoQ), 17% revenue growth QoQ, expanding prescriber base and payer access, successful PBM engagement, and improved liquidity from a debt draw. These operational and commercial wins are tempered by ongoing unprofitable quarterly results, negative adjusted EBITDA, rising SG&A and interest costs, anticipated higher gross-to-net pressures (mid-30s), and some inventory accounting timing effects. On balance, the company shows solid early launch traction and strengthened financial flexibility while still investing heavily toward profitability and additional product launches.View all PTHS earnings summariesPTHS Stock 12 Month Forecast
Average Price Target
$61.20
▲(136.11% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―